In last trading session, Regulus Therapeutics Inc (NASDAQ:RGLS) saw 1.85 million shares changing hands with its beta currently measuring 0.84. Company’s recent per share price level of $2.80 trading at $0.25 or 9.80% at ring of the bell on the day assigns it a market valuation of $185.48M. That closing price of RGLS’s stock is at a discount of -3.57% from its 52-week high price of $2.90 and is indicating a premium of 70.36% from its 52-week low price of $0.83. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 1.22 million if we extend that period to 3-months.
For Regulus Therapeutics Inc (RGLS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.26 in the current quarter.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Upright in the green during last session for gaining 9.80%, in the last five days RGLS remained trading in the green while hitting it’s week-highest on Thursday, 04/24/25 when the stock touched $2.80 price level, adding 3.45% to its value on the day. Regulus Therapeutics Inc’s shares saw a change of 77.22% in year-to-date performance and have moved 44.33% in past 5-day. Regulus Therapeutics Inc (NASDAQ:RGLS) showed a performance of 115.38% in past 30-days. Number of shares sold short was 2.66 million shares which calculate 1.36 days to cover the short interests.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 40.21% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -42.89% while estimates for its earnings growth in next 5 years are of -3.70%.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Insiders are in possession of 2.18% of company’s total shares while institution are holding 86.69 percent of that, with stock having share float percentage of 88.63%. Investors also watch the number of corporate investors in a company very closely, which is 86.69% institutions for Regulus Therapeutics Inc that are currently holding shares of the company. FEDERATED HERMES, INC. is the top institutional holder at RGLS for having 12.85 million shares of worth $22.94 million. And as of 2024-06-30, it was holding 19.9374 of the company’s outstanding shares.
The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 6.25 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6952 of outstanding shares, having a total worth of $11.16 million.
On the other hand, Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund and Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 7.88 shares of worth $22.07 million or 11.90% of the total outstanding shares. The later fund manager was in possession of 7.42 shares on Jan 31, 2025 , making its stake of worth around $20.77 million in the company or a holder of 11.20% of company’s stock.
